Virginia Kaklamani News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Virginia kaklamani. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Virginia Kaklamani Today - Breaking & Trending Today

SABCS 2023 Highlights Open the Door for More Key Data in 2024

Virginia Kaklamani, MD, discusses this year's sessions of interest and looks ahead to next year ....

San Antonio , United States , Greg Laub , Ut Health Sciences Center , Medpage Today , Virginia Kaklamani , Sciences Center , San Antonio Breast Cancer Symposium , Senior Director ,

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023

This new post hoc analysis of the Phase 3 EMERALD trial evaluatedelacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations.This analysisshows a clinically meaningful ....

United States , Elcin Barker Ergun , Menarini Stemline , Menarini Group , Elacestrant Clinical Development Program , Ut Health San Antonio , Menarini Group Stemline Therapeutic , Md Anderson Cancer Center , Stemline Therapeutics Inc , Stemline Therapeutics , Antonio Breast Cancer Symposium , Virginia Kaklamani , San Antonio , Safety Information , Stemline Therapeutic , Fetal Toxicity ,

Less-Frequent Surveillance Mammo Feasible in Older Breast Cancer Survivors

No difference for survival outcomes for annual versus around every 2 years ....

San Antonio , United States , Janet Dunn , University Of Warwick , San Antonio Breast Cancer , Virginia Kaklamani , Texas Health Sciences Center San Antonio ,

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023

This new post hoc analysis of the Phase 3 EMERALD trial evaluated elacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations. This analysis shows a clinically meaningful improvement in progression-free survival across the subgroups studied, including those patients with bone, liver and/or lung metastases, those with common […] ....

United States , Menarini Stemline , Elcin Barker Ergun , Menarini Industrie Farmaceutiche Riunite , Menarini Group Stemline Therapeutic , Md Anderson Cancer Center , Elacestrant Clinical Development Program , Menarini Group , Stemline Therapeutics Inc , Ut Health San Antonio , Stemline Therapeutics , Antonio Breast Cancer Symposium , Virginia Kaklamani , San Antonio , Safety Information , Stemline Therapeutic , Fetal Toxicity , Industrie Farmaceutiche ,

SABCS 2023 Includes New Data in Breast Cancer, Special Session on Disparities

Virginia Kaklamani, MD, previews sessions of interest and overviews what to look forward to heading into the San Antonio Breast Cancer Symposium (SABCS) 2023. ....

Ut Health San Antonio , Division Of Hematology Oncology , Virginia Kaklamani , San Antonio , San Antonio Breast Cancer Symposium , Breast Cancer ,